Eurofins Scientific SE (ERFSF)
| Previous close | 86.30 |
| Open | 88.34 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 86.30 - 86.30 |
| 52-week range | 82.82 - 151.96 |
| Volume | |
| Avg. volume | 540 |
| Market cap | 16.598B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 21.94 |
| EPS (TTM) | 3.93 |
| Earnings date | N/A |
| Forward dividend & yield | 0.81 (0.87%) |
| Ex-dividend date | 01 July 2021 |
| 1y target est | N/A |
- Business Wire
Health Canada approves Eurofins CDMO Alphora Inc.’s Standard Processing License for Synthetic Phytocannabinoids
LUXEMBOURG, May 10, 2022--Eurofins CDMO Alphora Inc. announces receipt in April 2022 of its Health Canada Standard Processing License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario Operations. This is complementary to the Institutional Research License obtained through Health Canada in June 2021 for its Mississauga development site.
- Business Wire
PAMM Foundation Outsources Its Laboratory Activities for Pathology and Medical Microbiology ("PAMM") to Eurofins Clinical Diagnostics Netherlands
LUXEMBOURG, May 09, 2022--Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing, announces that it has successfully signed an agreement with Stichting PAMM Laboratoria voor Pathologie en Medische Microbiologie ("PAMM"), a medical microbiology and pathology laboratory diagnostics company in The Netherlands.
- Business Wire
CORRECTING and REPLACING: Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 April 2022
LUXEMBOURG, May 03, 2022--Regulatory News: This replaces the announcement made at 1:56 PM CEST on May 3 due to the following corrections: "Exercise of stock options and warrants" instead of "Exercise of stock options" and "Vesting of free shares" instead of "Warrants vesting of free shares".
